Leading the Charge

We’ve built a company poised to produce transformative pharmaceutical solutions by bringing together leaders steeped in all the functional areas needed to bring new drugs to life. With a deeply skilled management team directing our day-to-day wins, and a Board with a stellar track record, we’re acquiring, developing and commercializing drug candidates for diseases where there is a high unmet medical need.

Meet Our Best & Brightest

Bringing products to market for patients with high unmet medical need. Managing quality and regulatory compliance for a global biotech company. Overseeing clinical development for top-flight pharmaceutical companies. These are the back stories of just some of the bright minds you’ll find in the lab, meeting room and beyond at Dova Pharmaceuticals.

Mark Hahn

Mark HahnChief Financial Officer

Mr. Hahn joined Dova as our Chief Financial Officer in January 2018. Previously he was the executive vice president and chief financial officer of Cempra, Inc. (NASDAQ: CEMP) from February 2010 to November 2017. From 2008 to 2009, Mr. Hahn was the chief financial officer of Athenix Corp., an agricultural biotechnology company, leading its merger with Bayer CropScience, where he served as finance director into 2010. Prior to Athenix, Mr. Hahn was the chief financial officer of various companies including GigaBeam Corporation, a telecommunications equipment company, BuildLinks, Inc. and PerformaWorks, Inc., software companies, and Charles & Colvard, Ltd., a consumer products company. Mr. Hahn began his career at Ernst & Young where he served in various capacities, culminating in senior manager from 1984 until 1996. Mr. Hahn holds a B.B.A. in accounting and finance from the University of Wisconsin-Milwaukee and is a certified public accountant in the State of Maryland and North Carolina.